NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2012

Primary Completion Date

January 24, 2018

Study Completion Date

April 5, 2028

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

belimumab 10mg/kg

belimumab 10mg/kg IV monthly

OTHER

placebo

Normal Saline 250 ml

Trial Locations (32)

2000

GSK Investigational Site, Rosario

5400

GSK Investigational Site, Santa Fe

10032

GSK Investigational Site, New York

10467

GSK Investigational Site, The Bronx

20010

GSK Investigational Site, Washington D.C.

28034

GSK Investigational Site, Madrid

30912

GSK Investigational Site, Augusta

45229

GSK Investigational Site, Cincinnati

46026

GSK Investigational Site, Valencia

63104

GSK Investigational Site, St Louis

78240

GSK Investigational Site, San Luis Potosí City

85016

GSK Investigational Site, Phoenix

119435

GSK Investigational Site, Moscow

194100

GSK Investigational Site, Saint Petersburg

445846

GSK Investigational Site, Tolyatti

C1270AAN

GSK Investigational Site, Capital Federal

T3B 6A8

GSK Investigational Site, Calgary

M5G 1X8

GSK Investigational Site, Toronto

474-8710

GSK Investigational Site, Aichi

890-8520

GSK Investigational Site, Kagoshima

989-3126

GSK Investigational Site, Miyagi

113-8519

GSK Investigational Site, Tokyo

Lima 27

GSK Investigational Site, Lima

Lima 33

GSK Investigational Site, Lima

Lima 5

GSK Investigational Site, Lima

91-738

GSK Investigational Site, Lodz

02-637

GSK Investigational Site, Warsaw

08950

GSK Investigational Site, Esplugues de Llobregat. Barcelona

BS2 8BJ

GSK Investigational Site, Bristol

L12 2AP

GSK Investigational Site, Liverpool

NW1 2PG

GSK Investigational Site, London

WC1N 3JH

GSK Investigational Site, London